Table 2.
Meta-analysis results of outcomes reported by studies comparing TAC vs. CsA a.
| Outcome | Study Design (N) | Time in months | Relative Risk b (95% CI) | Statistics c | |
|---|---|---|---|---|---|
| p | I2 | ||||
| CMV | RCT [23,24,29,61] (1519) | 12 | 0.85 (0.64, 1.15) | 0.30 | 0 |
| Diabetes | RCT [22,23,24,25,27,28,29,30,32,61] (2389) | 12 | 1.72 (1.17, 2.52) | 0.006 | 35 |
| Cohort [62,66] (738) | 36 | 2.71 (1.61, 4.57) | 0.0002 | 0 | |
| Dyslipidemia | RCT [29,30,61] (1435) | 12 | 0.75 (0.60, 0.94) | 0.01 | 0 |
| Hypertension | RCT [23,26,27,29,61] (1714) | 12 | 0.97 (0.82, 1.16) | 0.76 | 25 |
| Total Infections | RCT [23,24,25,61] (1376) | 12 | 1.03 (0.93, 1.14) | 0.55 | 12 |
| Lymphoceles | RCT [30,61] (1235) | 12 | 0.61 (0.34, 1.07) | 0.09 | 10 |
| Malignancies | RCT [23,29,61] (1459) | 12 | 1.16 (0.40, 3.38) | 0.79 | 0 |
| Withdraw | RCT [23,24,27,28,29,30,32,61] (2384) | 12 | 0.98 (0.34, 2.81) | 0.97 | 82 * |
a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with TAC. c p: p-value for relative risk estimation; I2: test for heterogeneity. * The high heterogeneity (p < 0.00001) could be caused by the following trials: Mayer 1997 [23], Hardinger 2005 [29] and Vicenti 1996 [32]. Sensitivity analysis showed much reduced heterogeneity (p = 0.23, I2 = 29%) when these trials were removed from the analysis.